280 related articles for article (PubMed ID: 37075316)
1. Cost-effectiveness analysis of ovarian function preservation with GnRH agonist during chemotherapy in premenopausal women with early breast cancer.
Huang Y; Huang X; Huang X; Lin S; Luo S; Gu D; Weng X; Xu X
Hum Reprod; 2023 Jun; 38(6):1099-1110. PubMed ID: 37075316
[TBL] [Abstract][Full Text] [Related]
2. Modeling of live-birth rates and cost-effectiveness of oocyte cryopreservation for cancer patients prior to high- and low-risk gonadotoxic chemotherapy.
Lyttle Schumacher B; Grover N; Mesen T; Steiner A; Mersereau J
Hum Reprod; 2017 Oct; 32(10):2049-2055. PubMed ID: 28938728
[TBL] [Abstract][Full Text] [Related]
3. Factors associated with ovarian function recovery after chemotherapy for breast cancer: a systematic review and meta-analysis.
Silva C; Caramelo O; Almeida-Santos T; Ribeiro Rama AC
Hum Reprod; 2016 Dec; 31(12):2737-2749. PubMed ID: 27664208
[TBL] [Abstract][Full Text] [Related]
4. A cost-effectiveness analysis of freeze-only or fresh embryo transfer in IVF of non-PCOS women.
Le KD; Vuong LN; Ho TM; Dang VQ; Pham TD; Pham CT; Norman RJ; Mol BWJ
Hum Reprod; 2018 Oct; 33(10):1907-1914. PubMed ID: 30239784
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of controlled ovarian stimulation using GnRH antagonist protocols for emergency fertility preservation in young women with breast cancer-a prospective nationwide Swedish multicenter study.
Marklund A; Eloranta S; Wikander I; Kitlinski ML; Lood M; Nedstrand E; Thurin-Kjellberg A; Zhang P; Bergh J; Rodriguez-Wallberg KA
Hum Reprod; 2020 Apr; 35(4):929-938. PubMed ID: 32313940
[TBL] [Abstract][Full Text] [Related]
6. Specifying the ovarian cancer risk threshold of 'premenopausal risk-reducing salpingo-oophorectomy' for ovarian cancer prevention: a cost-effectiveness analysis.
Manchanda R; Legood R; Antoniou AC; Gordeev VS; Menon U
J Med Genet; 2016 Sep; 53(9):591-9. PubMed ID: 27354448
[TBL] [Abstract][Full Text] [Related]
7. The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review.
Rodgers RJ; Reid GD; Koch J; Deans R; Ledger WL; Friedlander M; Gilchrist RB; Walters KA; Abbott JA
Hum Reprod; 2017 May; 32(5):1033-1045. PubMed ID: 28333356
[TBL] [Abstract][Full Text] [Related]
8. Gonadotropin-Releasing Hormone Agonists for Ovarian Function Preservation in Premenopausal Women Undergoing Chemotherapy for Early-Stage Breast Cancer: A Systematic Review and Meta-analysis.
Munhoz RR; Pereira AA; Sasse AD; Hoff PM; Traina TA; Hudis CA; Marques RJ
JAMA Oncol; 2016 Jan; 2(1):65-73. PubMed ID: 26426573
[TBL] [Abstract][Full Text] [Related]
9. The depot GnRH agonist protocol improves the live birth rate per fresh embryo transfer cycle, but not the cumulative live birth rate in normal responders: a randomized controlled trial and molecular mechanism study.
Xu B; Geerts D; Hu S; Yue J; Li Z; Zhu G; Jin L
Hum Reprod; 2020 Jun; 35(6):1306-1318. PubMed ID: 32478400
[TBL] [Abstract][Full Text] [Related]
10. Fertility preservation for women with breast cancer: a multicentre randomized controlled trial on various ovarian stimulation protocols.
Balkenende EME; Dahhan T; Beerendonk CCM; Fleischer K; Stoop D; Bos AME; Lambalk CB; Schats R; Smeenk JMJ; Louwé LA; Cantineau AEP; de Bruin JP; Linn SC; van der Veen F; van Wely M; Goddijn M
Hum Reprod; 2022 Jul; 37(8):1786-1794. PubMed ID: 35776109
[TBL] [Abstract][Full Text] [Related]
11. Ovulation triggering with hCG alone, GnRH agonist alone or in combination? A randomized controlled trial in advanced-age women undergoing IVF/ICSI cycles.
Zhou C; Yang X; Wang Y; Xi J; Pan H; Wang M; Zhou Y; Xiao Y
Hum Reprod; 2022 Jul; 37(8):1795-1805. PubMed ID: 35595223
[TBL] [Abstract][Full Text] [Related]
12. The risk of menopausal symptoms in premenopausal breast cancer patients and current pharmacological prevention strategies.
Lei YY; Yeo W
Expert Opin Drug Saf; 2021 Oct; 20(10):1163-1175. PubMed ID: 33951990
[No Abstract] [Full Text] [Related]
13. GnRH agonist leuprolide acetate does not confer any protection against ovarian damage induced by chemotherapy and radiation in vitro.
Bildik G; Akin N; Senbabaoglu F; Sahin GN; Karahuseyinoglu S; Ince U; Taskiran C; Selek U; Yakin K; Guzel Y; Ayhan C; Alper E; Cetiner M; Balaban B; Mandel NM; Esen T; Iwase A; Urman B; Oktem O
Hum Reprod; 2015 Dec; 30(12):2912-25. PubMed ID: 26466909
[TBL] [Abstract][Full Text] [Related]
14. Gonadotropin-Releasing Hormone Agonist Cotreatment During Chemotherapy May Increase Pregnancy Rate in Survivors.
Blumenfeld Z; Zur H; Dann EJ
Oncologist; 2015 Nov; 20(11):1283-9. PubMed ID: 26463871
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of embryo transfer strategies: a decision analytic model using long-term costs and consequences of singletons and multiples born as a consequence of IVF.
van Heesch MM; van Asselt AD; Evers JL; van der Hoeven MA; Dumoulin JC; van Beijsterveldt CE; Bonsel GJ; Dykgraaf RH; van Goudoever JB; Koopman-Esseboom C; Nelen WL; Steiner K; Tamminga P; Tonch N; Torrance HL; Dirksen CD
Hum Reprod; 2016 Nov; 31(11):2527-2540. PubMed ID: 27907897
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness of Gene-Specific Prevention Strategies for Ovarian and Breast Cancer.
Wei X; Sun L; Slade E; Fierheller CT; Oxley S; Kalra A; Sia J; Sideris M; McCluggage WG; Bromham N; Dworzynski K; Rosenthal AN; Brentnall A; Duffy S; Evans DG; Yang L; Legood R; Manchanda R
JAMA Netw Open; 2024 Feb; 7(2):e2355324. PubMed ID: 38334999
[TBL] [Abstract][Full Text] [Related]
17. Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data.
Lambertini M; Moore HCF; Leonard RCF; Loibl S; Munster P; Bruzzone M; Boni L; Unger JM; Anderson RA; Mehta K; Minton S; Poggio F; Albain KS; Adamson DJA; Gerber B; Cripps A; Bertelli G; Seiler S; Ceppi M; Partridge AH; Del Mastro L
J Clin Oncol; 2018 Jul; 36(19):1981-1990. PubMed ID: 29718793
[TBL] [Abstract][Full Text] [Related]
18. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
19. Gonadotropin-releasing hormone agonists for ovarian protection during cancer chemotherapy: systematic review and meta-analysis.
Senra JC; Roque M; Talim MCT; Reis FM; Tavares RLC
Ultrasound Obstet Gynecol; 2018 Jan; 51(1):77-86. PubMed ID: 29055060
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up to assess criteria for ovarian tissue cryopreservation for fertility preservation in young women and girls with cancer.
Duffin K; Howie R; Kelsey TW; Wallace HB; Anderson RA
Hum Reprod; 2023 Jun; 38(6):1076-1085. PubMed ID: 37011633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
